Discussing China's current hair loss landscape, a concerning trend emerges: mounting life pressures are driving hair loss toward younger demographics.
Data released by Alibaba Health in 2017 revealed that 38% of those experiencing hair loss were born in the 1980s, while a staggering 36% belonged to the post-1990s generation!This indicates a significant lowering of the average age among China's hair loss population, with those born in the 1990s joining the "main force" of hair loss sufferers. Even teenagers in their early teens are prematurely experiencing hair loss troubles, helplessly facing a "midlife crisis" far too early.
Faced with this increasingly severe hair loss problem, medical experts and pharmaceutical companies are working tirelessly to find better treatment solutions.Since minoxidil's introduction in the last century, its safety profile and efficacy in promoting hair regrowth have become increasingly well-documented. It remains an FDA-approved topical medication for treating hair loss. Yet, the majority of patients still blindly substitute certified medications with health supplements, often ignoring early symptoms or even avoiding medical consultation altogether.
Last year, Alibaba released a health report based on DaBar data analysis, revealing another aspect of how people tend to downplay early hair loss issues, opting for self-diagnosis and self-treatment rather than seeking professional medical advice. This reflects both our insufficient understanding of hair loss as a common condition and the fact that early hair loss, due to its minimal impact on appearance, often fails to garner attention.
When consumers blindly navigate the complex market, they risk delaying or even worsening their condition. Scalp and hair follicle care is a long-term commitment. By the time users realize their products offer no improvement—or have caused deterioration—precious time has already been lost.A healthy hair strand undergoes a metabolic cycle from growth phase to resting phase before shedding, a process spanning 2 to 7 years. The number of hair follicles on the scalp is fixed and non-renewable. For hair loss issues, choosing the wrong treatment approach can lead to significant follicle atrophy or even necrosis. By the time noticeable thinning prompts a search for professional medical help, the optimal treatment window has often been missed.
Making the Right Choice to Escape the Agony
Under normal circumstances, people shed approximately 70 to 100 hairs daily. If daily hair loss exceeds 100 strands and persists for over a month, it warrants attention.Doctors emphasize that abnormal hair loss is a health concern requiring rational medical intervention. For non-pathological hair loss, focus on a light diet, regular routines, adequate sleep, increased exercise, and gentle scalp massage to enhance blood circulation, restore healthy scalp metabolism, and revitalize hair follicles. If diagnosed with pathological hair loss, timely and appropriate medication is essential for active treatment.
Currently, the primary clinically validated and therapeutically effective drug components remain oral finasteride and topical minoxidil.Compared to oral finasteride, topical treatments like Mandi deliver minoxidil directly to hair follicles, offering greater targeting with fewer side effects. This makes them a safer, more effective choice favored by both doctors and patients, especially for those with mild initial symptoms. However, minoxidil's current adoption rate remains limited, and public understanding of its mechanism and efficacy in treating hair loss is often incomplete.
Clinical trials indicate minoxidil is an active metabolite that stimulates hair growth. Appropriate doses promote proliferation and differentiation of follicular epithelial cells, increasing the number of dermal papillae, hair matrix cells, outer root sheath cells, and perihair fibroblast synthesis, thereby extending the anagen (growth) phase.simultaneously promoting angiogenesis to enhance blood supply to the dermal papilla vascular network, thereby improving nutrient delivery for hair growth. Additionally, minoxidil inhibits the suppressive effect of epidermal growth factor on hair growth, further aiding in hair regrowth. Through these multiple mechanisms, minoxidil demonstrates clear therapeutic efficacy for various forms of alopecia.
Produced by Zhejiang Wansheng Pharmaceutical Co., Ltd. (a subsidiary of Shenyang Sansheng Pharmaceutical), Mandi contains 5% minoxidil concentration and is an NMPA-certified OTC topical treatment for hair loss. Beyond focusing on potent, targeted medications, this pharmaceutical company is leveraging its successful hair loss treatment experience to develop daily shampoo products better suited for early, subtle hair loss.The introduction of such products is expected to help reduce delayed treatment in China caused by insufficient attention to mild to moderate hair loss through preventive healthcare. Simultaneously, for patients already diagnosed and undergoing medication, these products developed by professional pharmaceutical companies can provide reliable and safe adjunctive therapy to enhance treatment efficacy.